- Symeres has partnered with Ambagon Therapeutics to evaluate molecular glues for potential use in colorectal cancer and other diseases.
- The collaboration will involve in vitro assays, mechanistic studies, and profiling across 102 cancer cell lines to assess therapeutic potential.
Symeres has entered a collaboration with Ambagon Therapeutics to explore a class of small molecules known as molecular glues for potential applications in colorectal cancer and other hard-to-target diseases.
The partnership will focus on evaluating Ambagon’s molecular glues using in vitro assays and mechanistic studies. The work includes assessing ternary complex kinetics through surface plasmon resonance (ResidenceTimer™), alongside cellular assays to measure functional effects on disease-related pathways.
Additional analyses will include fluorescence microscopy to study inhibition of target protein nuclear translocation, as well as downstream pathway evaluation using quantitative polymerase chain reaction (qPCR) and Western blot techniques. The therapeutic potential of the compounds will also be tested using cancer cell viability assays.
Symeres will further support the program through its synthesis and validation services, including profiling across a panel of 102 cancer cell lines. The collaboration aligns with its CRDMO capabilities in drug discovery and development, supporting early-stage research that may inform future contract manufacturing pathways.
“Targeting previously undruggable proteins remains one of the key challenges in oncology drug discovery. By combining Ambagon’s molecular glue technology with our translational research capabilities, we aim to generate meaningful insights to accelerate preclinical development across a variety of therapeutic conditions.”
Jorg Benningshof, Managing Director, Oncolines, a Symeres company
